.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Accenture
Cerilliant
Chubb
Medtronic
Citi
Boehringer Ingelheim
Cantor Fitzgerald
QuintilesIMS
Covington

Generated: July 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,858,122

« Back to Dashboard

Which drugs does patent 7,858,122 protect, and when does it expire?


Patent 7,858,122 protects KEPPRA XR and is included in one NDA. There has been one Paragraph IV challenge on Keppra XR.

This patent has nineteen patent family members in seventeen countries.

Summary for Patent: 7,858,122

Title:Extended release formulation of levetiracetam
Abstract:An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system.
Inventor(s): Kshirsagar; Rajesh (Vadodara, IN), Joshi; Mayank (Vadodara, IN), Raichandani; Yogesh (Vododara, IN)
Assignee: UCB Pharma S.A. (Brussels, BE)
Application Number:11/215,947
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ucb Inc
KEPPRA XR
levetiracetam
TABLET, EXTENDED RELEASE;ORAL022285-001Sep 12, 2008ABRXYesNo7,858,122► SubscribeY
Ucb Inc
KEPPRA XR
levetiracetam
TABLET, EXTENDED RELEASE;ORAL022285-002Feb 12, 2009ABRXYesYes7,858,122► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,858,122

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India81/MUM/2005Jan 27, 2005

Non-Orange Book Patents for Patent: 7,858,122

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,863,316Extended release formulation of Levetiracetam► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,858,122

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101111245► Subscribe
Australia2005325930► Subscribe
BrazilPI0518506► Subscribe
Germany05815688► Subscribe
Eurasian Patent Organization200701575► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Farmers Insurance
Argus Health
US Army
Queensland Health
Healthtrust
Chinese Patent Office
Cantor Fitzgerald
UBS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot